Slide 1: Ipsen Q1 2018 Sales
Ipsen Q1 2018 Sales April 26, 2018
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements in
Slide 3: Q1 2018 financial highlights
Q1 2018 financial highlights ▪ Group sales growth of +23.1%(1) at constant exchange rates ▪ Specialty Care sales growth of +27.4%(1) driven by continued Somatuline® growth and contribution from the launches of Cabometyx ® and Onivyde ® ▪ Consumer Healthcare back to growth confirmed at +6.4%(1) - adj
Slide 4: Q1 2018 pipeline achievements
Q1 2018 pipeline achievements Cabometyx® ▪ 2L HCC – EMA Regulatory submission (EU) ▪ 1L RCC – Positive CHMP opinion (EU), EMA approval expected in Q2 2018 Continued expansion of Cabometyx market potential 4
Slide 5: Oncology launch update
Oncology launch update Cabometyx® Onivyde® ▪ Sales growth of 37%(1) from Q4 2017 to Q1 ▪ Sales growth of 28%(1) from Q4 2017 to Q1 2018, positively impacted by inventory 2018, reflecting progressive ramp in the build-up in newly reimbursed territories U.S. and growing sales to European ▪ Reimburseme
Slide 6: Sales growth driven by Specialty Care
Q1 2018 sales growth driven by Specialty Care Net sales Q1 2018 in million euros – % excluding foreign exchange impact Group Sales €510.3m Somatuline® 196 +25% +23.1% Specialty Care Decapeptyl® 83 +9% Cabometyx® 28 Specialty Care Onivyde® €440.4m 24 +27.4% Dysport® 84 +5% Nutropin® 12 -8% Increlex®
Slide 7: Q&A
Q&A David Meek, CEO Aymeric Le Chatelier, CFO 7